Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplemental Methods: Incubations with time-dependent CYP-selective inhibitors.
Supplemental Table S1. Donor information for CYP2C19-genotyped human liver microsomes (HLM).
Supplemental Table S2. Summary of CBD and CBD metabolites detected by LC-MS/MS.
Supplemental Figure S1. Representative LC-MS/MS chromatogram and MS-MS product ion spectra and predicted fragmentation patterns of CBD and metabolite standards.
Supplemental Figure S2. Representative LC-MS/MS chromatograms of CBD metabolites formed in HLM in the presence and absence of the metabolic cofactors NADPH and UDPGA.
Supplemental Figure S3. Representative LC-MS/MS chromatograms of CBD metabolites formed in HLM in the presence and absence of CYP-selective chemical inhibitors.
Supplemental Figure S4. 7-OH-CBD formation in the presence of time-dependent CYPselective inhibitors.
Supplemental Figure S5. Effect of CYP-selective chemical inhibitors on 7-OH-CBD metabolism.
Supplemental Figure S6. Effect of CYP2C19, CYP2D6, and CYP3A inhibition on 7-OH-CBD depletion and 7-COOH-CBD formation.
Supplemental Figure S7. Metabolism of 7-OH-CBD by recombinant CYP enzymes.
Supplemental Figure S8. Representative LC-MS/MS chromatogram and MS-MS product ion spectra of CBD metabolites produced by recombinant CYP2C19.
Supplemental Figure S9. Representative LC-MS/MS chromatogram and MS-MS product ion spectra of CBD metabolites produced by recombinant CYP3A4.
Supplemental Figure S10. Deuterated cannabinoid metabolite formation by rCYP2C19, rCYP3A4, and HLM.
Supplemental Figure S11. CYP2C19 activity, as measured by S-mephenytoin 4'-hydroxylation, in individual CYP2C19-genotyped HLM.
Supplemental Reference
- Supplemental Data -